Comparison of inflammation-based prognostic scores as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 9, 2014, Pages 682-688

  Yamamura, Kazuo ^a   Sugimoto, Hiroyuki ^a   Kanda, Mitsuro ^a   Yamada, Suguru ^a   Nomoto, Shuji ^a   Nakayama, Goro ^a   Fujii, Tsutomu ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer recurrence; Hepatocellular carcinoma; Inflammation based prognostic score

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; COMPARATIVE EFFECTIVENESS; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL TO LYMPHOCYTE RATIO; PLATELET TO LYMPHOCYTE RATIO; PREDICTIVE VALUE; PROGNOSTIC INDEX; PROGNOSTIC NUTRITIONAL INDEX; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; UNIVARIATE ANALYSIS; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR INVASION; VERY ELDERLY;

TUMOR MARKER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84906335068     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.114     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990; 211: 277-287.
3. el-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N,. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery. 1997; 122: 571-577.
4. Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, et al. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007; 95: 311-316.
5. Kim H, Park MS, Park YN, Kim H, Kim KS, Choi JS, et al. Preoperative radiologic and postoperative pathologic risk factors for early intra-hepatic recurrence in hepatocellular carcinoma patients who underwent curative resection. Yonsei Med J. 2009; 50: 789-795.
6. Chong CC, Lee KF, Ip PC, Wong JS, Cheung SY, Wong J, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? Surgeon. 2012; 10: 260-266.
7. Kaibori M, Saito T, Matsui Y, Uchida Y, Ishizaki M, Kamiyama Y,. A review of the prognostic factors in patients with recurrence after liver resection for hepatocellular carcinoma. Am J Surg. 2007; 193: 431-437.
8. Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL, et al. Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol. 2001; 19: 3037-3044.
9. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38: 200-207.
10. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007; 141: 330-339.
11. Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E,. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbecks Arch Surg. 2010; 395: 625-632.
12. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545.
13. Mantovani A, Allavena P, Sica A, Balkwill F,. Cancer-related inflammation. Nature. 2008; 454: 436-444.
14. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002; 420: 860-867.
15. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell. 2010; 140: 883-899.
16. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ,. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; 60: 184-190.
17. Han HS, Cho JY, Yoon YS, Ahn KS, Kim H,. Preoperative inflammation is a prognostic factor for gallbladder carcinoma. Br J Surg. 2011; 98: 111-116.
18. Cho JY, Han HS, Yoon YS, Hwang DW, Jung K, Kim JH, et al. Preoperative cholangitis and metastatic lymph node have a negative impact on survival after resection of extrahepatic bile duct cancer. World J Surg. 2012; 36: 1842-1847.
19. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012; 33: 749-756.
20. Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010; 25: 1427-1433.
21. Chiang SF, Hung HY, Tang R, Changchien CR, Chen JS, You YT, et al. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis. 2012; 27: 1347-1357.
22. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T,. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012; 23: 265-273.
23. Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010; 17: 52-58.
24. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A,. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011; 98: 268-274.
25. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T,. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012; 203: 101-106.
26. Mano Y, Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg. 2013; 258: 301-305.
27. Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008; 32: 1757-1762.
28. Pinato DJ, North BV, Sharma R,. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012; 106: 1439-1445.
29. Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T,. Criteria for safe hepatic resection. Am J Surg. 1995; 169: 589-594.
30. Midorikawa Y, Kubota K, Takayama T, Toyoda H, Ijichi M, Torzilli G, et al. A comparative study of postoperative complications after hepatectomy in patients with and without chronic liver disease. Surgery. 1999; 126: 484-491.
31. Sugimoto H, Okochi O, Hirota M, Kanazumi N, Nomoto S, Inoue S, et al. Early detection of liver failure after hepatectomy by indocyanine green elimination rate measured by pulse dye-densitometry. J Hepatobiliary Pancreat Surg. 2006; 13: 543-548.
32. Pringle JH,. V. Notes on the arrest of hepatic hemorrhage due to trauma. Ann Surg. 1908; 48: 541-549.
33. Couinaud C,. Lobes et segments hepatiques-notes sur larchitecture anatomique et chirurgicale du foie. Presse Med. 1954; 62: 709-712.
34. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60: 646-649.
35. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg. 1989; 19: 98-129.
36. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
37. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
38. Fu SJ, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, et al. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. Med Oncol. 2013; 30: 721-726.
39. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH,. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003; 6: 283-287.
40. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011; 54: 948-955.
41. Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013; 58: 58-64.
42. Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L,. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009; 125: 1640-1648.
43. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182: 4499-4506.
44. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010; 70: 3052-3061.
45. Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep. 2012; 28: 453-458.
46. Huang YH, Wu JC, Lui WY, Chau GY, Tsay SH, Chiang JH, et al. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg. 2000; 24: 551-555.
47. Lai EC, Lo CM, Fan ST, Liu CL, Wong J,. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998; 133: 183-188.
48. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N,. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 2001; 91: 2378-2385.
49. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012; 255: 8-17.
50. Wang SN, Chuang SC, Lee KT,. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res. 2014; 44: 523-531.